https://doi.org/10.4081/uij.2012.e8

Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome

Vol. 26 No. 1 (2012)
Submitted: 8 August 2011
Accepted: 11 May 2012
Published: 7 June 2012
anti-IgE treatment, interstitial cystitis/ bladder pain syndrome, omalizumab.
Abstract Views: 1588
PDF: 491
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Daniele Porru
danieleporru@tin.it
Urology Department, IRCCS San Matteo Hospital, Pavia, Italy.
Enrica Bucchioni
Novartis Italia, Origgio (VA), Italy.
Marcello Macchi
Urology Department, IRCCS San Matteo Hospital, Pavia, Italy.
Fabio Leva
Urology Department, IRCCS San Matteo Hospital, Pavia, Italy.
Alberto Parmigiani
Urology Department, IRCCS San Matteo Hospital, Pavia, Italy.
Davide Barletta
Urology Department, IRCCS San Matteo Hospital, Pavia, Italy.
Dimitrios Choussos
Urology Department, IRCCS San Matteo Hospital, Pavia, Italy.
Barbara Gardella
Obstetric and Gynecology Clinics IRCCS San Matteo Hospital, Pavia, Italy.
Maria Diletta Daccò
Obstetric and Gynecology Clinics IRCCS San Matteo Hospital, Pavia, Italy.
Rossella Elena Nappi
Obstetric and Gynecology Clinics IRCCS San Matteo Hospital, Pavia, Italy.
Massimo Allegri
Pain Therapy Service Fondazione IRCCS Policlinico San Matteo, Department of Resuscitation and Organ Transplantation surgery sciences, Section of Anesthesiology and Resuscitation, University of Pavia, Italy.
Carlo Maria Bianchi
School of Specialization in Urology, University of Pavia,, Italy.
Arsenio Spinillo
Obstetric and Gynecology Clinics IRCCS San Matteo Hospital, Pavia, Italy.
Bruno Rovereto
Urology Department, IRCCS San Matteo Hospital, Pavia,, Italy.
The aim of this study was to evaluate the efficacy of omalizumab in the treatment of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), evaluated by visual analogue score for pain and urgency- frequency, O’Leary-Sant IC symptom and problem index questionnaire, Pain Urgency Frequency questionnaire and Patient Global Assessment questionnaire. Four female patients with a diagnosis of IC/BPS were included in the study, with an age between 20 and 39 years. In the first patient the subjective final evaluation was of a marked improvement. The second patient had a moderate improvement of the subjective final evaluation. The third patient considered her overall clinical situation to have slightly improved after treatment. One 32-year-old patient, with multiple allergies, discontinued treatment after 3 months and could not complete the study due to side effects. Omalizumab was subcutaneously administered to patients with IC/PBS; it induced both a subjective and objective improvement of symptoms in 2 patients enrolled in the study.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

Novartis

How to Cite

Porru, D., Bucchioni, E., Macchi, M., Leva, F., Parmigiani, A., Barletta, D., Choussos, D., Gardella, B., Daccò, M. D., Nappi, R. E., Allegri, M., Bianchi, C. M., Spinillo, A., & Rovereto, B. (2012). Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome. Urogynaecologia, 26(1), e8. https://doi.org/10.4081/uij.2012.e8

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

An Open Access Publication is one that meets the following two conditions:

  1. the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.
  2. a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.